Prostate cancer prognosis linked to prostate-specific antigen levels below threshold

by Wiley

edited by Gaby Clark, reviewed by Alexander Pol

Gaby Clark

Scientific Editor

Meet our editorial team
Behind our editorial process

Alexander Pol

Deputy Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add as preferred source

After treatment for metastatic prostate cancer, a drop in prostate-specific antigen (PSA) levels in the blood is an indicator that treatment is working. A recent real-world study indicates that reaching a PSA level below 0.2 ng/mL is an indicator of improved patient survival. The study is published online in CANCER.

Multiple phase 3 clinical trials have shown that a PSA level below 0.2 ng/mL is the best cutoff for determining a patient's prognosis. Real-world data are lacking, however, and physicians often use other metrics, such as percentage of PSA decline, to assess treatment response. To determine whether there is a PSA response target associated with the most favorable outcome in community-dwelling adults with metastatic prostate cancer, investigators analyzed Veterans Health Administration data on 4,890 patients who received testosterone deprivation therapy with or without other treatments in 2018–2023 for metastatic hormone-sensitive prostate cancer.

Over a median follow-up of approximately 2 years, 896 patients died. Patients whose PSA levels dropped below 0.2 ng/mL within 9 months of starting treatment were 54% less likely to die than patients whose levels did not drop this low, whether their PSA levels also decreased by at least 90% or not. Patients who had at least a 90% PSA decline but did not achieve a PSA level of less than 0.2 ng/mL had no improvement in survival. The findings suggest that patients who do not experience a PSA drop below 0.2 ng/mL could be candidates for more aggressive treatments. Also, patients who received testosterone deprivation therapy plus another drug to further block testosterone were more likely to reach a PSA level below 0.2 ng/mL.

"These data show that we need to target a PSA below 0.2 ng/mL as our metric of success to optimize outcomes for our patients with metastatic prostate cancer," said corresponding author Stephen J. Freedland, M.D., professor of urology at Cedars-Sinai and staff physician at the Durham VA Medical Center.

Publication details

How low do you need to go? Association between various prostate-specific antigen response measures and clinical outcomes in metastatic castration‑sensitive prostate cancer in the Veterans Health Administration data, Cancer (2026). DOI: 10.1002/cncr.70494

Journal information: Cancer

Key medical concepts

Survival

Clinical categories

UrologyOncologyMen's health Provided by Wiley Who's behind this story?

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Alexander Pol

PhD nano-engineering from Delft University. Published researcher and journal reviewer. Brings scientific insight to content standards. Full profile →

Citation: Prostate cancer prognosis linked to prostate-specific antigen levels below threshold (2026, August 10) retrieved 11 August 2026 from https://medicalxpress.com/news/2026-08-prostate-cancer-prognosis-linked-specific.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.